abirateron medac 500mg potahovaná tableta
medac gesellschaft für klinische spezialpräparate m.b.h., wedel array - 19572 abirateron-acetÁt - potahovaná tableta - 500mg - abirateron
seroxat 20mg potahovaná tableta
glaxosmithkline (ireland) limited, dublin array - 15320 hemihydrÁt paroxetin-hydrochloridu - potahovaná tableta - 20mg - paroxetin
seroxat 30mg potahovaná tableta
glaxosmithkline (ireland) limited, dublin array - 15320 hemihydrÁt paroxetin-hydrochloridu - potahovaná tableta - 30mg - paroxetin
sorafenib stada 200mg potahovaná tableta
stada arzneimittel ag, bad vilbel array - 17664 sorafenib-tosilÁt - potahovaná tableta - 200mg - sorafenib
sorafenib stada 400mg potahovaná tableta
stada arzneimittel ag, bad vilbel array - 17664 sorafenib-tosilÁt - potahovaná tableta - 400mg - sorafenib
stimuloton 50mg potahovaná tableta
egis pharmaceuticals plc, budapešť array - 13950 sertralin-hydrochlorid - potahovaná tableta - 50mg - sertralin
tatica 250mg potahovaná tableta
egis pharmaceuticals plc, budapešť array - 19572 abirateron-acetÁt - potahovaná tableta - 250mg - abirateron
tatica 500mg potahovaná tableta
egis pharmaceuticals plc, budapešť array - 19572 abirateron-acetÁt - potahovaná tableta - 500mg - abirateron
sorafenib accord
accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastická činidla - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
akeega
janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostaty, nádorů, kastrace-odolné - antineoplastická činidla - treatment of adult patients with prostate cancer.